Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
memo - Magazine of European Medical Oncology
Published in: memo - Magazine of European Medical Oncology 1/2019

Open Access 01-03-2019 | Prostate Cancer | review

ESMO 2018—personal highlights

Published in: memo - Magazine of European Medical Oncology | Issue 1/2019

Login to get access

Summary

This article intends to summarize personal highlights of the ESMO (European Society for Medical Oncology) 2018 meeting and does not aim to give a comprehensive overview. We will summarize the most recent presented data on the treatment of non-small cell lung establishing first-line combinational therapies (chemotherapy backbone with immunotherapy) as standard of care. Furthermore highly practice relevant data on the treatment of recurrent or metastatic head and neck squamous cell carcinoma were presented. Next the treatment landscape of metastatic prostate cancer is changing rapidly and some new aspects in metastatic disease are reported.
Literature
1.
Cappuzzo F, McCleod M, Hussein M, et al. LBA53IMpower130: Progression-free survival (PFS) and safety analysis from a randomised phase III study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC. Ann Oncol. 2018;29:mdy424.065–mdy424.065.CrossRef
2.
Barlesi F, Nishio M, Cobo M, et al. LBA54IMpower132: efficacy of atezolizumab (atezo) + carboplatin (carbo)/cisplatin (cis) + pemetrexed (pem) as 1L treatment in key subgroups with stage IV non-squamous non-small cell lung cancer (NSCLC). Ann Oncol. 2018;29:mdy424.066–mdy424.066.CrossRef
3.
Gandhi L, Rodriguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378:2078–92.CrossRef
4.
Planchard D, Popat S, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv192–iv237.CrossRef
5.
Burtness B, Harrington KJ, Greil R, et al. LBA8_PRKEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Ann Oncol. 2018;29:mdy424.045–mdy424.045.CrossRef
6.
Saad F, Carles J, Gillessen S, et al. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. Lancet Oncol. 2016;17:1306–16.CrossRef
7.
Hoyle AP, Ali SA, James ND, et al. LBA4Effects of abiraterone acetate plus prednisone/prednisolone in high and low risk metastatic hormone sensitive prostate cancer. Ann Oncol. 2018;29:mdy424.033–mdy424.033.
8.
Parker CC, James ND, Brawley C, et al. LBA5_PRRadiotherapy (RT) to the primary tumour for men with newly-diagnosed metastatic prostate cancer (PCa): survival results from STAMPEDE. Ann Oncol. 2018;29:mdy424.034–mdy424.034.CrossRef
9.
Herden J, Heidegger I, Paffenholz P, Porres D. Systemic medical treatment in men with metastatic castration-resistant prostate cancer: recommendations for daily routine. Oncol Res Treat. 2015;38:654–68.CrossRef
10.
Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213–23.CrossRef
11.
Smith MR, Parker CC, Saad F, et al. LBA30ERA 223: A phase III trial of radium-223 (Ra-223) in combination with abiraterone acetate and prednisone/prednisolone for the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve patients (pts) with bone-predominant metastatic castration-resistant prostate cancer (mCRPC). Ann Oncol. 2018;29:mdy424.035–mdy424.035.
Metadata
Title
ESMO 2018—personal highlights
Publication date
01-03-2019
Published in
memo - Magazine of European Medical Oncology / Issue 1/2019
Print ISSN: 1865-5041
Electronic ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-019-0474-9

Other articles of this Issue 1/2019

memo - Magazine of European Medical Oncology 1/2019 Go to the issue

short review

Diffuse large B‑cell lymphoma

review

Surgical concepts in esophageal cancer

case report

Central nervous system-predominant Erdheim–Chester disease mimicking meningioma responding to BRAF inhibitor therapy: the importance of molecular diagnosis and targeted therapy in rare neoplastic disorders

review

Toxicities in B‑cell non-Hodgkin lymphoma—new agents, new pitfalls

review

Current lymphoma diagnostic standards: the pathologists’ view

short review

Radiochemotherapy in esophageal cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits